Literature DB >> 9144023

Lipoprotein(a): structural implications for pathophysiology.

M L Koschinsky1, S M Marcovina.   

Abstract

The assembly between a low-density lipoprotein particle and apolipoprotein(a), a highly carbohydrate-rich protein, gives origin to a peculiar class of lipoproteins, only found in the hedgehog, primates, and humans, termed lipoprotein(a). Apolipoprotein(a), which shares a high degree of sequence homology with the fibrinolytic proenzyme plasminogen, is linked to the apolipoprotein B-100 component of low-density lipoprotein via a disulfide bond and confers distinct biochemical and metabolic properties to lipoprotein(a). Because of its peculiar structural features and the observed correlation between high lipoprotein(a) levels and the development of a variety of atherosclerotic disorders, this lipoprotein has become the focus of an intense research effort. Although accumulation of lipoprotein(a) in the vessel wall at sites of vascular injury has been clearly evidenced, the mechanism(s) by which lipoprotein(a) exerts its pathogenic effect in this milieu remain largely unknown. It has been hypothesized that the pathological effect of lipoprotein(a) is related either to its similarity to low-density lipoprotein (i.e., a pro-atherogenic effect) or to the apolipoprotein(a) similarity to plasminogen (i.e., a pro-thrombotic/anti-fibrinolytic effect). However, it is probable that both components contribute to the pathogenicity of lipoprotein(a). The fact that lipoprotein(a) levels are largely genetically determined, varying widely among individuals and racial groups, adds additional elements to the scientific interest that surrounds this lipoprotein. Both clinical and biochemical studies of lipoprotein(a) have been complicated by the high degree of structural heterogeneity of apolipoprotein(a), which is considered the most polymorphic protein in human plasma. Our aim in this paper is to provide an overview of the most salient structural features of lipoprotein(a) and their possible pathophysiological implications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144023     DOI: 10.1007/bf02827238

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  6 in total

Review 1.  Lipoprotein(a) and coronary heart disease risk.

Authors:  S M Marcovina; R A Hegele; M L Koschinsky
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

2.  Immunopathology of desialylation: human plasma lipoprotein(a) and circulating anti-carbohydrate antibodies form immune complexes that recognize host cells.

Authors:  P S Sabarinath; P S Appukuttan
Journal:  Mol Cell Biochem       Date:  2015-01-30       Impact factor: 3.396

Review 3.  Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Tina Tran; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2011-07-12       Impact factor: 1.894

4.  High-resolution crystal structure of apolipoprotein(a) kringle IV type 7: insights into ligand binding.

Authors:  Q Ye; M N Rahman; M L Koschinsky; Z Jia
Journal:  Protein Sci       Date:  2001-06       Impact factor: 6.725

5.  Behçet's Disease as a Model of Venous Thrombosis.

Authors:  Micaela La Regina; Armen Yuri Gasparyan; Francesco Orlandini; Domenico Prisco
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

6.  Lipoprotein(a) level as a predictor of cardiovascular disease and small apoliprotein(a) isoforms in dialysis patients: assay-related differences are important.

Authors:  J Craig Longenecker; Josef Coresh; Michael J Klag; Neil R Powe; Nancy E Fink; Santica M Marcovina
Journal:  Clin Chim Acta       Date:  2008-07-18       Impact factor: 3.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.